<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476424</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 081</org_study_id>
    <nct_id>NCT00476424</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects</brief_title>
  <official_title>A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Education, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Pharmacokinetic study of once daily Efavirenz 400 mg versus 600 mg in Thai HIV-1 infected
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efavirenz Pharmacokinetic evaluation supports once-daily dosing (T1/2 is 10-52 hours). The
      recommended dosage of efavirenz in combination with nucleoside reverse transcriptase
      inhibitor (NRTI) and/or protease inhibitor (PI) is 600mg orally, once daily.

      In Thai populations, many ARV levels are very high. We believe that 600 mg efavirenz is too
      high for Thai people and would like to see the pharmacokinetic data and safety and efficacy
      of efavirenz at 400 mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess whether the low dose efavirenz is not inferior to the standard dose of efavirenz in terms of plasma concentration</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Access efavirenz plasma level after discontinuation of this medication</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg EFV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg EFV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
    <description>EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years of age or older with HIV-1 infection

          -  Who are on stable PI-based highly active antiretroviral therapy and have HIV-1 RNA &lt;50
             copies/ml within 6 months.

          -  No active opportunistic infection.

          -  Sexually active subjects must be willing to use an effective form of birth control.

          -  Able to provide written informed consent.

        Exclusion Criteria:

          -  Pregnant or breast-feeding females are excluded.

          -  Inability to understand the nature and extent of the study and the procedures
             required.

          -  ALT/ AST more than 5x upper limit

          -  Relevant history or current condition, illness that might interfere with drug
             absorption, distribution, metabolism or excretion.

          -  Use of concomitant medication that may interfere with the pharmacokinetics of efavienz

          -  History of sensitivity/idiosyncrasy to the drug or chemically related compounds which
             may be employed in the study.

          -  Active drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiat Ruxrungtham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2007</study_first_submitted>
  <study_first_submitted_qc>May 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>June 4, 2010</last_update_submitted>
  <last_update_submitted_qc>June 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kiat Ruxrungtham</name_title>
    <organization>HIV-NAT</organization>
  </responsible_party>
  <keyword>once daily Efavirenz 400 mg</keyword>
  <keyword>PK once daily Efavirenz 400 mg versus 600 mg</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

